| A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment AM Stein, T Demuth, D Mobley, M Berens, LM Sander Biophysical journal 92 (1), 356-365, 2007 | 282 | 2007 |
| An algorithm for extracting the network geometry of three‐dimensional collagen gels AM Stein, DA Vader, LM Jawerth, DA Weitz, LM Sander Journal of microscopy 232 (3), 463-475, 2008 | 224 | 2008 |
| Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia KT Mueller, E Waldron, SA Grupp, JE Levine, TW Laetsch, MA Pulsipher, ... Clinical cancer research 24 (24), 6175-6184, 2018 | 206 | 2018 |
| The micromechanics of three‐dimensional collagen‐I gels AM Stein, DA Vader, DA Weitz, LM Sander Complexity 16 (4), 22-28, 2011 | 193 | 2011 |
| Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3 MO Nowicki, N Dmitrieva, AM Stein, JL Cutter, J Godlewski, Y Saeki, ... Neuro-oncology 10 (5), 690-699, 2008 | 154 | 2008 |
| Tisagenlecleucel model‐based cellular kinetic analysis of chimeric antigen receptor–T cells AM Stein, SA Grupp, JE Levine, TW Laetsch, MA Pulsipher, MW Boyer, ... CPT: pharmacometrics & systems pharmacology 8 (5), 285-295, 2019 | 97 | 2019 |
| Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities K Venkatakrishnan, LE Friberg, D Ouellet, JT Mettetal, A Stein, IF Trocóniz, ... Clinical Pharmacology & Therapeutics 97 (1), 37-54, 2015 | 95 | 2015 |
| Bcr–abl transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment AM Stein, D Bottino, V Modur, S Branford, J Kaeda, JM Goldman, ... Clinical Cancer Research 17 (21), 6812-6821, 2011 | 54 | 2011 |
| A model for glioma growth E Khain, LM Sander, AM Stein Complexity 11 (2), 53-57, 2005 | 44 | 2005 |
| Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors V Goel, E Hurh, A Stein, J Nedelman, J Zhou, O Chiparus, PH Huang, ... Cancer chemotherapy and pharmacology 77, 745-755, 2016 | 41 | 2016 |
| Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial A Stein, W Wang, AA Carter, O Chiparus, N Hollaender, H Kim, RJ Motzer, ... BMC cancer 12, 1-10, 2012 | 41 | 2012 |
| Chimeric antigen receptor T cell therapies: a review of cellular kinetic‐pharmacodynamic modeling approaches A Chaudhury, X Zhu, L Chu, A Goliaei, CH June, JD Kearns, AM Stein The Journal of Clinical Pharmacology 60, S147-S159, 2020 | 37 | 2020 |
| Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial A Stein, J Bellmunt, B Escudier, D Kim, SG Stergiopoulos, W Mietlowski, ... European urology 64 (6), 994-1002, 2013 | 35 | 2013 |
| Predicting the onset of nonlinear pharmacokinetics AM Stein, LA Peletier CPT: pharmacometrics & systems pharmacology 7 (10), 670-677, 2018 | 18 | 2018 |
| AFIR: a dimensionless potency metric for characterizing the activity of monoclonal antibodies AM Stein, R Ramakrishna CPT: pharmacometrics & systems pharmacology 6 (4), 258-266, 2017 | 18 | 2017 |
| Estimating the cell density and invasive radius of three-dimensional glioblastoma tumor spheroids grown in vitro AM Stein, MO Nowicki, T Demuth, ME Berens, SE Lawler, EA Chiocca, ... Applied Optics 46 (22), 5110-5118, 2007 | 18 | 2007 |
| Preservation of T-cell stemness with a novel expansionless CAR-T manufacturing process, which reduces manufacturing time to less than two days, drives enhanced CAR-T cell efficacy B Engels, X Zhu, J Yang, A Price, A Sohoni, AM Stein, L Parent, M Greene, ... Blood 138, 2848, 2021 | 17 | 2021 |
| Chimeric antigen receptors and uses thereof A Abujoub, J Blankenship, A Bondanza, J Brogdon, D Bu, S De Vita, ... US Patent App. 17/104,983, 2021 | 17 | 2021 |
| Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems S Ahmed, M Ellis, H Li, L Pallucchini, AM Stein Journal of pharmacokinetics and pharmacodynamics 46, 287-304, 2019 | 16 | 2019 |
| Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia AM Stein, G Martinelli, TP Hughes, MC Müller, L Beppu, E Gottardi, ... BMC cancer 13, 1-10, 2013 | 16 | 2013 |
